Citation

Lee SH, Yun SJ, Ryu S, Choi SW, Kim HJ, Kang TK, Oh SC, Cho SJ. Signa Vitae 2018; 14(2): 75-77.

Copyright

(Copyright © 2018, Pharmamed Mado)

DOI

10.22514/SV142.102018.12

PMID

unavailable

Abstract

Levodopa-carbidopa-entacapone is a single combination drug consisting of levodopa (aromatic amino acid), carbidopa (dopa-decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase inhibitor). The Food and Drug Administration approved levodopa-carbidopaentacapone in 2003, as treatment for idiopathic Parkinson's disease in patients experiencing signs and symptoms of wearing-off. Although various adverse drug reactions of levodopa-carbidopa-entacapone have been recorded, there has been no reported case of levodopa-carbidopa-entacapone overdose. We report the first case of signs and symptoms of an overdose of levodopa-carbidopa-entacapone (levodopa: 3000 mg; carbidopa: 750 mg; entacapone: 6000 mg) in a suicide attempt, presenting as altered mentality, xanthoderma, and yellowish sclera without hyperbilirubinemia. © 2018, Pharmamed Mado Ltd. All rights reserved.

Language: en

Keywords

Toxicology; Drug overdose; Parkinson’s disease; Levodopa-carbidopa-entacapone; Xanthoderma; Yellowish sclera